Anti-pseudomonas aeruginosa immune globulin

Drug Profile

Anti-pseudomonas aeruginosa immune globulin

Alternative Names: Anti-pseudomonas aeruginosa gamma-globulin; Anti-pseudomonas aeruginosa IgY; Anti-Pseudomonas aeruginosa immunoglobulin Y; Anti-pseudomonas IgY; IgY; Pseudomonas aeruginosa immune globulin

Latest Information Update: 22 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator IMMUNSYSTEM
  • Class Antibacterials; Immunotherapies; Polyclonal antibodies
  • Mechanism of Action Cell movement inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Cystic fibrosis-associated respiratory tract infections

Most Recent Events

  • 21 Sep 2015 Phase-I/II development for Cystic fibrosis-associated respiratory tract infections (Prevention) is ongoing in Sweden (NCT00633191)
  • 01 Dec 2012 IMMUNSYSTEM completes its phase I/II trial for Cystic fibrosis-associated respiratory tract infections (Prevention) in Sweden (NCT00633191)
  • 23 Mar 2012 IMMUNSYSTEM completes enrolment in its phase I/II trial for Cystic fibrosis-associated respiratory tract infections (Prevention) in Sweden (NCT00633191)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top